Recent trends in the epidemiology and treatment of C. difficile infection in children

Current Opinion in Pediatrics

Volumn 25, Issue 1, 2013, Pages 116-121

  Sammons, Julia Shaklee ^a   Toltzis, Philip ^b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Clostridium difficile; pediatrics; review

Indexed keywords

ANTIBIOTIC AGENT; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; ENEMA; FIDAXOMICIN; METRONIDAZOLE; MONOCLONAL ANTIBODY; NITAZOXANIDE; PROBIOTIC AGENT; PROTON PUMP INHIBITOR; RIFAXIMIN; TIGECYCLINE; VANCOMYCIN;

ABDOMINAL PAIN; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIBODY RESPONSE; CHILD HOSPITALIZATION; CHILDHOOD DISEASE; CLOSTRIDIUM DIFFICILE INFECTION; COLON FLORA; CRYPTOSPORIDIOSIS; DEATH; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG MEGADOSE; ENTERITIS; FECES ANALYSIS; GASTROINTESTINAL SYMPTOM; GIARDIASIS; HEALTH CARE PERSONNEL; HIGH RISK PATIENT; HOSPITALIZED CHILD; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION RISK; INTESTINE FLORA; JEJUNOSTOMY TUBE; LENGTH OF STAY; LOW DRUG DOSE; META ANALYSIS (TOPIC); MICROBIOME; NONHUMAN; ORGAN TRANSPLANTATION; OUTPATIENT; PATHOGENESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REVIEW; RISK FACTOR; SEPSIS; STOMACH TUBE; SYSTEMATIC REVIEW (TOPIC); TOXIC MEGACOLON; TREATMENT FAILURE; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ANTI-BACTERIAL AGENTS; CHILD; CLOSTRIDIUM DIFFICILE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HUMANS; INCIDENCE; RISK FACTORS;

EID: 84873085923     PISSN: 10408703     EISSN: 1531698X     Source Type: Journal    
DOI: 10.1097/MOP.0b013e32835bf6c0     Document Type: Review

References (64)

1. Bartlett JG, Chang TW, Gurwith M, et al. Antibiotic-Associated pseudomembranous colitis due to toxin-producing clostridia. N Engl J Med 1978; 298:531-534
2. Dubberke ER, Olsen MA. Burden of Clostridium difficile on the healthcare system. Clin Infect Dis 2012; 55 (SUPPL2):S88-S92
3. Lucado J, Gould C, Elixhauser A. Clostridium difficile infections (CDI) in hospital stays, 2009: Statistical Brief #124. 2011
4. Surveillance for community-Associated Clostridium difficile: Connecticut, 2006. Morb Mortal Wkly Rep 2008; 57:340-343
5. Severe Clostridium difficile-Associated disease in populations previously at low risk: Four states, 2005. Morb Mortal Wkly Rep 2005; 54:1201-1205
6. Vital signs: Preventing Clostridium difficile infections. Morb Mortal Wkly Rep 2012; 61:157-162
7. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31:431-455
8. Kutty PK, Woods CW, Sena AC, et al. Risk factors for and estimated incidence of community-Associated Clostridium difficile infection, North Carolina, USA. Emerg Infect Dis 2010; 16:197-204
9. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin genevariant strain of Clostridium difficile. N Engl J Med 2005; 353:2433-2441
10. Goorhuis A, Bakker D, Corver J, et al. Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. Clin Infect Dis 2008; 47:1162-1170
11. Loo VG, Poirier L, Miller MA, et al A predominantly clonal multiinstitutional outbreak of Clostridium difficile-Associated diarrhea with high morbidity and mortality. N Engl J Med 2005; 353:2442-2449
12. Kim J, Smathers SA, Prasad P, et al. Epidemiological features of Clostridium difficile-Associated disease among inpatients at children's hospitals in the United States, 2001-2006. Pediatrics 2008; 122:1266-1270
13. Zilberberg MD, Shorr AF, Kollef MH. Increase in Clostridium difficile-related hospitalizations among infants in the United States, 2000-2005. Pediatr Infect Dis J 2008; 27:1111-1113
14. Benson L, Song X, Campos J, Singh N. Changing epidemiology of Clostridium difficile-Associated disease in children. Infect Control Hosp Epidemiol 2007; 28:1233-1235
15. Zilberberg MD, Tillotson GS, McDonald C. Clostridium difficile infections among hospitalized children, United States, 1997-2006. Emerg Infect Dis 2010; 16:604-609
16. Nylund CM, Goudie A, Garza JM, et al. Clostridium difficile infection in hospitalized children in the United States. Arch Pediatr Adolesc Med 2011; 165:451-457
17. Baker SS, Faden H, Sayej W, et al. Increasing incidence of communityassociated atypical Clostridium difficile disease in children. Clin Pediatr (Phila) 2010; 49:644-647
18. Chen KT, Stephens DJ, Anderson E, et al. Clostridium difficile infection in the pediatric surgery population. J Pediatr Surg 2012; 47:1385-1389
19. Toltzis P, Kim J, Dul M, et al. Presence of the epidemic North American Pulsed Field type 1 Clostridium difficile strain in hospitalized children. J Pediatr 2009; 154:607-608
20. Kim J, Shaklee JF, Smathers S, et al. Risk factors and outcomes associated with severe Clostridium difficile infection in children. Pediatr Infect Dis J 2012; 31:134-138
21. Lukkarinen H, Eerola E, Ruohola A, et al. Clostridium difficile ribotype 027-Associated disease in children with norovirus infection. Pediatr Infect Dis J 2009; 28:847-848
22. DennoDM, Shaikh N, Stapp JR, et al. Diarrhea etiology in a pediatric emergency department: A case control study. Clin Infect Dis 2012; 55:897-904
23. Shaklee J, Zerr DM, Elward A, et al. Improving surveillance for pediatric Clostridium difficile infection: Derivation and validation of an accurate casefinding tool. Pediatr Infect Dis J 2011; 30:e38-e40
24. Klein EJ, Boster DR, Stapp JR, et al. Diarrhea etiology in a Children's Hospital Emergency Department: A prospective cohort study. Clin Infect Dis 2006; 43:807-813
25. Sandora TJ, Fung M, Flaherty K, et al. Epidemiology and risk factors for Clostridium difficile infection in children. Pediatr Infect Dis J 2011; 30:580-584.
26. Pokorn M, Radsel A, Cizman M, et al. Severe Clostridium difficile-Associated disease in children. Pediatr Infect Dis J 2008; 27:944-946
27. Angel CA, Green J, Swischuk L, Patel J. Severe ciprofloxacin-Associated pseudomembranous colitis in an eight-year-old child. J Pediatr Surg 2004; 39:1590-1592
28. Patel A, Gossett JJ, Benton T, et al. Fulminant Clostridium difficile toxic megacolon in a pediatric heart transplant recipient. Pediatr Transplant 2012; 16:E30-E34
29. McFarland LV. Update on the changing epidemiology of Clostridium difficileassociated disease. Nat Clin Pract Gastroenterol Hepatol 2008; 5:40-48
30. Owens RC Jr, Donskey CJ, Gaynes RP, et al. Antimicrobial-Associated risk factors for Clostridium difficile infection. Clin Infect Dis 2008; 46 (SUPPL1): S19-S31
31. Morinville V, McDonald J. Clostridium difficile-Associated diarrhea in 200 Canadian children. Can J Gastroenterol 2005; 19:497-501
32. Mezoff E, Mann EA, Hart KW, et al. Clostridium difficile infection and treatment in the pediatric inflammatory bowel disease population. J Pediatr Gastroenterol Nutr 2011; 52:437-441
33. Banaszkiewicz A, Kowalska-Duplaga K, Pytrus T, et al. Clostridium difficile infection in newly diagnosed pediatric patients with inflammatory bowel disease: Prevalence and risk factors. Inflamm Bowel Dis 2012; 18:844-848
34. Kelsen JR, Kim J, Latta D, et al. Recurrence rate of clostridium difficile infection in hospitalized pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis 2011; 17:50-55
35. Castagnola E, Battaglia T, Bandettini R, et al. Clostridium difficile-Associated disease in children with solid tumors. Support Care Cancer 2009; 17:321-324
36. van de Wetering MD, Kuijpers TW, Taminiau JA, et al. Pseudomembranous and neutropenic enterocolitis in pediatric oncology patients. Support Care Cancer 2003; 11:581-586
37. Tai E, Richardson LC, Townsend J, et al. Clostridium difficile infection among children with cancer. Pediatr Infect Dis J 2011; 30:610-612
38. Deshpande A, Pant C, Pasupuleti V, et al. Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-Analysis. Clin Gastroenterol Hepatol 2012; 10:225-233
39. Kwok CS, Arthur AK, Anibueze CI, et al. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: Meta-Analysis. Am J Gastroenterol 2012; 107:1011-1019
40. Janarthanan S, Ditah I, Adler DG, Ehrinpreis MN. Clostridium difficileassociated diarrhea and proton pump inhibitor therapy: A meta-Analysis. Am J Gastroenterol 2012; 107:1001-1010
41. JumpRL, Pultz MJ, Donskey CJ. Vegetative Clostridium difficile survives in room air on moist surfaces and in gastric contents with reduced acidity: A potential mechanism to explain the association between proton pump inhibitors and C. difficile-Associated diarrheä Antimicrob Agents Chemother 2007; 51: 2883-2887
42. Turco R, Martinelli M, Miele E, et al. Proton pump inhibitors as a risk factor for paediatric Clostridium difficile infection. Aliment Pharmacol Ther 2010; 31:754-759
43. Rexach CE, Tang-Feldman YJ, Cantrell MC, Cohen SH. Epidemiologic surveillance of Clostridium difficile diarrhea in a freestanding pediatric hospital and a pediatric hospital at a university medical center. Diagn Microbiol Infect Dis 2006; 56:109-114
44. Johnson S, Homann SR, Bettin KM, et al. Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole A randomized, placebo-controlled trial. Ann Intern Med 1992; 117:297-302
45. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-Associated diarrhea, stratified by disease severity. Clin Infect Dis 2007; 45:302-307
46. Recommendations for preventing the spread of vancomycin resistance. Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). Morb Mort Wkly Rep 1995; 44:1-13
47. Al-Nassir WN, Sethi AK, Li Y, et al. Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-Associated disease. Antimicrob Agents Chemother 2008; 52:2403-2406
48. Aslam S, Hamill RJ, Musher DM. Treatment of Clostridium difficile-Associated disease: Old therapies and new strategies. Lancet Infect Dis 2005; 5:549-557
49. Johnson S. Recurrent Clostridium difficile infection: A review of risk factors, treatments, and outcomes. J Infect 2009; 58:403-410
50. Kamboj M, Khosa P, Kaltsas A, et al. Relapse versus reinfection: Surveillance of Clostridium difficile infection. Clin Infect Dis 2011; 53:1003-1006
51. Venugopal AA, Johnson S. Fidaxomicin: A novel macrocyclic antibiotic approved for treatment of Clostridium difficile infection. Clin Infect Dis 2011; 54:568-574
52. Cornely OA, Crook DW, Esposito R, et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: A double-blind, noninferiority, randomised controlled trial. Lancet Infect Dis 2012; 12:281-289
53. Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011; 364:422-431
54. Musher DM, Logan N, Bressler AM, et al. Nitazoxanide versus vancomycin in Clostridium difficile infection: A randomized, double-blind study. Clin Infect Dis 2009; 48:e41-e46
55. Venugopal AA, Johnson S. Current state of Clostridium difficile treatment options. Clin Infect Dis 2012; 55 (SUPPL2):S71-S76
56. Herpers BL, Vlaminckx B, Burkhardt O, et al. Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection. Clin Infect Dis 2009; 48:1732-1735
57. Dendukuri N, Costa V, McGregor M, Brophy JM. Probiotic therapy for the prevention and treatment of Clostridium difficile-Associated diarrhea: A systematic review. CMAJ 2005; 173:167-170
58. McFarland LV, Surawicz CM, Greenberg RN, et al A randomized placebocontrolled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994; 271:1913-1918
59. Surawicz CM, McFarland LV, Greenberg RN, et al. The search for a better treatment for recurrent Clostridium difficile disease: Use of highdose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 2000; 31:1012-1017
60. Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis 2011; 53:994-1002
61. Kyne L, Warny M, Qamar A, Kelly CP. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 2001; 357:189-193
62. Leung DY, Kelly CP, Boguniewicz M, et al. Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin. J Pediatr 1991; 118:633-637
63. Salcedo J, Keates S, Pothoulakis C, et al. Intravenous immunoglobulin therapy for severe Clostridium difficile colitis. Gut 1997; 41:366-370
64. Lowy I, Molrine DC, Leav BA, et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 2010; 362:197-205